Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, ...
STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE — A study based on IRIS Registry data delved into the rates, risk factors, management strategies and ...
A new study explains not only why some patients with wet age-related macular degeneration (or 'wet' AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used ...
An intraocular implant that releases the corticosteroid fluocinolone acetonide into the eye over a period of months has been shown to significantly reduce the need for injections of anti–vascular ...
The demand for intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is forecasted to increase by about 50% over the next 5 years in Denmark, due largely to an aging population, a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...
Combined phacoemulsification with DEX-I leads to superior CMT reduction and comparable visual acuity improvement compared to anti-VEGF injections. The study found significant intra-group CMT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results